drugset
Drugs / NoV GI.1/GII.4 Bivalent VLP Vaccine
last change Jan 2013 re-read 3 minutes ago

NoV GI.1/GII.4 Bivalent VLP Vaccine

also known as Norovirus Bivalent GI.1/GII.4 VLP Vaccine · Norovirus Bivalent VLP Vaccine

Vaccine

Developed for
gastroenteritis
Investigated by
Takeda

Trials 1

today NCT01168401 · Ph 1
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01168401 Sep 2010 → Jan 2013 gastroenteritis Takeda Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NoV GI.1/GII.4 Bivalent VLP Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01168401 ↗
Known as Norovirus Bivalent GI.1/GII.4 VLP Vaccine “Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)” NCT01168401 ↗
Known as Norovirus Bivalent VLP Vaccine “Intramuscular (IM) Norovirus Bivalent VLP Vaccine adjuvanted with MPL and Al(OH)3 compared to controls.” NCT01168401 ↗
Modality Vaccine “Intramuscular (IM) Norovirus Bivalent VLP Vaccine adjuvanted with MPL and Al(OH)3 compared to controls.” NCT01168401 ↗
Route Intramuscular “Participants will receive two doses, by IM injection, 28 days apart.” NCT01168401 ↗